---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-26-000052"
form_type: "8-K"
ticker: "BHC"
cik: "0000885590"
company_name: "Bausch Health Companies Inc."
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:52:21.647647+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bausch + Lomb closes $2.8B term loan refinancing, reduces margins, extends maturity

## Summary
- Closed $2.802B Replacement Term Loans maturing 2031 to refinance existing term B loans due 2028 and 2031.
- Interest margin reduced by 0.50% (vs prior 2031 loans) and 0.25% (vs 2028 loans); SOFR+3.75% or ABR+2.75%.
- Amortization at 1.00% per annum, first installment payable June 30, 2026.
- Effective maturity extension of the 2028 loans from September 2028 to January 2031.

## SEC filing metadata
- accession: 0000950103-26-000052
- form_type: 8-K
- ticker: BHC
- cik: 0000885590
- company_name: Bausch Health Companies Inc.
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885590/000095010326000052/0000950103-26-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885590/000095010326000052/dp239511_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-26-000052
- JSON: https://secwatch.observer/filing/0000950103-26-000052.json
- Plain text: https://secwatch.observer/filing/0000950103-26-000052.txt

## Key facts
- Debt Financings
  Bausch Health Companies Inc. amended term loan of $2,802,125,000 with JPMorgan Chase Bank, N.A. at (i) 3.75% per annum for Replacement Term Loans with an interest rate determined maturing January 15, 2031.
  - Instrument: term loan
  - Principal: $2,802,125,000
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Rate: (i) 3.75% per annum for Replacement Term Loans with an interest rate determined
  - Maturity: January 15, 2031
  - Event: amendment
  source text: The Fourth Amendment provides for a new $2,802,125,000 tranche of term loans maturing in 2031 (the "Replacement Term Loans"), the proceeds of which were used to refinance all of Bausch + Lomb’s outstanding term B loans due 2031 (the "Third Amendment Term Loans") and term B loans due 2028 (the "First Incremental Term Loans").
  evidence_url: https://www.sec.gov/Archives/edgar/data/885590/000095010326000052/0000950103-26-000052-index.htm
- Material Agreements
  Bausch Health Companies Inc. amended Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank (effective 2026-01-02).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank
  - Effective: 2026-01-02
  source text: On January 2, 2026, Bausch + Lomb Corporation (“Bausch + Lomb”), a subsidiary of Bausch Health Companies Inc., entered into an amendment (the “Fourth Amendment”) to the Credit and Guaranty Agreement, dated as of May 10, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/885590/000095010326000052/0000950103-26-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.